LOGO
LOGO

Acrivon Secures Nearly $130 Mln Private Placement Financing, Stock Soars

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024

Acrivon Therapeutics Inc. (ACRV), a clinical stage biopharmaceutical company, has announced a $130 million private placement financing.

Through the private investment in public equity ("PIPE") financing with certain existing and new accredited investors, the company will issue and sell an aggregate of 8.235 million shares of its common stock at a price of $8.50 per share, and pre-funded warrants to purchase up to an aggregate of 7.06 million shares of common stock at a purchase price of $8.499 per pre-funded warrant.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update -June 15 - June 19, 2026

June 19, 2026 16:46 ET
Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.